Compare HWKN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | EWTX |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1995 | 2021 |
| Metric | HWKN | EWTX |
|---|---|---|
| Price | $132.72 | $44.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $200.00 | $39.00 |
| AVG Volume (30 Days) | 172.3K | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $1,083,696,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | $34.02 | ★ N/A |
| Revenue Growth | ★ 11.21 | N/A |
| 52 Week Low | $117.98 | $12.31 |
| 52 Week High | $186.15 | $48.40 |
| Indicator | HWKN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 62.42 |
| Support Level | $128.75 | $29.03 |
| Resistance Level | $156.86 | N/A |
| Average True Range (ATR) | 7.15 | 2.71 |
| MACD | -2.28 | 0.62 |
| Stochastic Oscillator | 6.18 | 69.29 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.